Needham & Company
View Older Stories
-
Companies with NDRs 09/26
-
Needham & Company Downgrades NuVasive (NUVA) to Hold
-
NuVasive (NUVA) De-Risked, Buy on Weakness - Needham & Company
-
NuVasive (NUVA) PT Raised to $80 at Needham & Company
-
NuVasive (NUVA) PT Lowered to $67 at Needham & Company
-
NuVasive (NUVA) PT Lowered to $70 at Needham & Company, Keeps 'Buy'
-
Needham & Company Double Upgrades NuVasive (NUVA) to Buy
-
K2M Warning is a Negative Read-Through for Globus Medical (GMED) and NuVasive (NUVA) - Needham & Company
-
Pre-Open Movers 08/28: (IXYS) (KITE) (JUNO) Higher; (TRV) (MET) (ALL) Lower (more...)
-
Needham & Company Downgrades NuVasive (NUVA) to Underperform
-
NuVasive (NUVA) Hold Rating Maintained at Needham & Company Despite Growth Rebound
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Notable Analyst Rating Changes 5/27: (CAL) (VSLR) (NUVA) Upgraded; (WDAY) (SIG) (AAPL) Downgraded
-
Notable Analyst Rating Changes 10/6: (CSAL) (FDX) (NUVA) Upgraded; (HPY) (CMA) (TDY) Downgraded
-
NuVasive (NUVA) CEO Departure Has Mixed Implications, Needham & Company Says
-
Needham & Company Downgrades NuVasive (NUVA) to Hold
-
Notable Analyst Rating Changes 08/08: (GRPN) (MSFT) (LOW) Upgraded; (FIO) (HTA) (TGT) Downgraded
-
Needham & Company Starts NuVasive (NUVA) at Buy, $28 PT
-
Notable Analyst Rating Changes 10/04: (EBAY) (AMD) (EIX) Upgraded; (S) (NUVA) (PCS) Downgraded
-
Needham & Company Maintains a 'Hold' on NuVasive (NUVA); Company Optimistic About Long-Term Growth Drivers; We Remain Cautious On Limited Revenue Growth Visibility
-
Unusual 11 Mid-Day Movers 10/29: FMR, MWW, EONC, VVUS, TNAV, CSTR Higher; NR, NUVA, SNBC, EXAS, GRRF Lower
-
NuVasive (NUVA) Shares Plummet on Weak Outlook; Analysts Downgrade at 8 Firms
-
Morning Movers 10/29: FMR, VVUS, MWW, CSTR, TNAV, PTEK, AXTI, EL Higher; NUVA, NR, AMAG, VLCM, TNCC, SNBC, EXAS Lower
-
Notable Analyst Rating Changes 10/29: MWW, VVUS, MS, LVS Upgraded; FSLR, MEOH, NUVA, AVP Downgraded
-
NuVasive (NUVA) Shares Downgraded at 8 Firms: JPMorgan, BMO, Needham, Stifel, William Blair, Cowen, Leerink, Capstone
-
Needham & Company Maintains a 'Strong Buy' on NuVasive (NUVA); Guidance Changes Relieve Overhang on Stock
-
Needham & Company Reiterates a 'Strong Buy' Rating on NuVasive (NUVA); Management Expected To Take A Cautious Position
-
Needham & Company Reiterates a 'Strong Buy' on NuVasive (NUVA); Continued Market Share Gains Lead to 2Q10 Beat
-
Needham & Company Reiterates a 'Strong Buy' on NuVasive (NUVA); Analyst Day Highlighted Development Projects
-
Needham & Company Reiterates a 'Strong Buy' on NuVasive (NUVA); 1Q10 In-Line; Company Reaffirmed Guidance
-
Needham & Company Reiterates a 'Strong Buy' on NuVasive (NUVA)
-
Needham & Company Upgrades NuVasive (NUVA) to Strong Buy
-
Needham & Co Upgrades NuVasive (NUVA) to Buy
-
Needham Upgrades NuVasive (NUVA) to Buy
-
Needham & Co Downgrades NuVasive (NUVA) to Hold; Lowers Estimates for 2009-10
-
Needham & Co's Top MedTech Picks: MDT, SYK, ISRG, NUVA

